Abstract:Direct cell reprogramming, also called transdifferentiation, allows for the reprogramming of one somatic cell type directly into another, without the need to transition through an induced pluripotent state. Thus, it is an attractive approach to develop novel tissue engineering applications to treat diseases and injuries where there is a shortage of proliferating cells for tissue repair. In certain tissue damage, terminally differentiated somatic cells lose their ability to proliferate, as a result, damaged tissues cannot heal by themselves. Examples of these scenarios include myocardial infarctions, neurodegenerative diseases, and cartilage injuries. Transdifferentiation is capable of reprogramming cells that are abundant in the body into desired cell phenotypes that are able to restore tissue function in damaged areas. Therefore, direct cell reprogramming is a promising direction in the cell and tissue engineering and regenerative medicine fields. In recent years, several methods for transdifferentiation have been developed, ranging from the overexpression of transcription factors via viral vectors, to small molecules, to clustered regularly interspaced short palindromic repeats (CRISPR) and its associated protein (Cas9) for both genetic and epigenetic reprogramming. Overexpressing transcription factors by use of a lentivirus is currently the most prevalent technique, however it lacks high reprogramming efficiencies and can pose problems when transitioning to human subjects and clinical trials. CRISPR/Cas9, fused with proteins that modulate transcription, has been shown to improve efficiencies greatly. Transdifferentiation has successfully generated many cell phenotypes, including endothelial cells, skeletal myocytes, neuronal cells, and more. These cells have been shown to emulate mature adult cells such that they are able to mimic major functions, and some are capable of promoting regeneration of damaged tissue in vivo. While transdifferentiated cells have not yet seen clinical use, they have had promise in mice models, showing success in treating liver disease and several brain-related diseases, while also being utilized as a cell source for tissue engineered vascular grafts to treat damaged blood vessels. Recently, localized transdifferentiated cells have been generated in situ, allowing for treatments without invasive surgeries and more complete transdifferentiation. In this review, we summarized the recent development in various cell reprogramming techniques, their applications in converting various somatic cells, their uses in tissue regeneration, and the challenges of transitioning to a clinical setting, accompanied with potential solutions.

Direct Reprogramming in Bone and Joint Degenerative Diseases: Applications, Obstacles and Directions

Dedifferentiation-like Reprogramming of Degenerative Nucleus Pulposus Cells into Notochordal-Like Cells by Defined Factors

Direct conversion of fibroblasts to osteoblasts as a novel strategy for bone regeneration in elderly individuals

Direct cell reprogramming: approaches, mechanisms and progress

Next-generation direct reprogramming

Progress and Challenges of Cell Replacement Therapy for Neurodegenerative Diseases Based on Direct Neural Reprogramming

Cell Reprogramming Strategies for Treating Osteoarthritis and Intervertebral Disc Degeneration

Incorporating protein transduction domains (PTD) within recombinant ‘fusion’ transcription factors. A novel strategy for directing stem cell differentiation?

Direct cell reprogramming for tissue engineering and regenerative medicine

Overcoming Current Dilemma in Cartilage Regeneration: Will Direct Conversion Provide a Breakthrough?

Direct Lineage Reprogramming to Neural Cells

Direct Conversion of Somatic Cells into Induced Neurons

Direct reprogramming: converting one type of terminally differentiated cell directly into another

Improving the Reprogramming Efficiency of Somatic Cells to Induced Pluripotent Stem Cells.

Direct Cardiac Reprogramming in the Age of Computational Biology

Unlocking the potential of exosomes: a breakthrough in the theranosis of degenerative orthopaedic diseases

Systematic review on the application of 3D-bioprinting technology in orthoregeneration: current achievements and open challenges

Recent advances and future prospects in direct cardiac reprogramming

High-Resolution Dissection of Chemical Reprogramming from Mouse Embryonic Fibroblasts into Fibrocartilaginous Cells

Direct Reprogramming of Mouse Subchondral Bone Osteoblasts into Chondrocyte-like Cells

The Progress of Stem Cell Technology for Skeletal Regeneration